Brussels, 15/06/2005 (Agence Europe) - On Wednesday the European Commission fined Anglo-Swedish group AstraZeneca €60 million for misusing the patent system and the procedures for marketing pharmaceuticals to block or delay market entry for generic competitors to its ulcer drug Losec. The competition spokesperson explained that from 1993 to 2000 AstraZeneca infringed EC and EEA competition rules by blocking or delaying market access for generic versions of Losec and preventing parallel...